With an ever increasing older population the problems associated with age related neurodegenerative diseases are becoming more prevalent. The mission of Neu-Age Therapeutics is to develop pharmaceuticals that prevent the progression of conditions such as Alzheimer’s Disease, Parkinson’s Disease, Amyotrophic Lateral Sclerosis and other mitochondrial neurodegenerative disorders. All of these debilitating disorders have certain pathologies in common: insoluble protein aggregates (mis-folded proteins) that are associated with mitochondrial dysfunction. There is compelling evidence that these insoluble protein aggregates are a consequence of oxidative stress. The primary source of free radicals (reactive oxygen species, superoxides) that lead to oxidative stress and damage are generated from the electron transport chain, located in the mitochondria. It is well established that modulation of the mitochondrial membrane potential can have a profound influence on the generation of reactive oxygen species. It is possible to stop 90% of reactive oxygen species being produced without disrupting the normal metabolic production of energy (ATP).

Reduced oxidative damage – Helping neurons – An improved quality of life.

Neu-Age Therapeutics is dedicated to pursuing this goal.